Literature DB >> 9259030

Pharmacokinetic modelling of intravenous tobramycin in adolescent and adult patients with cystic fibrosis using the nonparametric expectation maximization (NPEM) algorithm.

D J Touw1, A A Vinks, C Neef.   

Abstract

The availability of personal computer programs for individualizing drug dosage regimens has stimulated the interest in modelling population pharmacokinetics. Data from 82 adolescent and adult patients with cystic fibrosis (CF) who were treated with intravenous tobramycin because of an exacerbation of their pulmonary infection were analysed with a non-parametric expectation maximization (NPEM) algorithm. This algorithm estimates the entire discrete joint probability density of the pharmacokinetic parameters. It also provides traditional parametric statistics such as the means, standard deviation, median, covariances and correlations among the various parameters. It also provides graphic-2- and 3-dimensional representations of the marginal densities of the parameters investigated. Several models for intravenous tobramycin in adolescent and adult patients with CF were compared. Covariates were total body weight (for the volume of distribution) and creatinine clearance (for the total body clearance and elimination rate). Because of lack of data on patients with poor renal function, restricted models with non-renal clearance and the non-renal elimination rate constant fixed at literature values of 0.15 L/h and 0.01 h-1 were also included. In this population, intravenous tobramycin could be best described by median (+/-dispersion factor) volume of distribution per unit of total body weight of 0.28 +/- 0.05 L/kg, elimination rate constant of 0.25 +/- 0.10 h-1 and elimination rate constant per unit of creatinine clearance of 0.0008 +/- 0.0009 h-1/(ml/min/1.73 m2). Analysis of populations of increasing size showed that using a restricted model with a non-renal elimination rate constant fixed at 0.01 h-1, a model based on a population of only 10 to 20 patients, contained parameter values similar to those of the entire population and, using the full model, a larger population (at least 40 patients) was needed.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9259030     DOI: 10.1023/a:1008633526772

Source DB:  PubMed          Journal:  Pharm World Sci        ISSN: 0928-1231


  15 in total

1.  MW/Pharm, an integrated software package for drug dosage regimen calculation and therapeutic drug monitoring.

Authors:  J H Proost; D K Meijer
Journal:  Comput Biol Med       Date:  1992-05       Impact factor: 4.589

2.  Estimation of population characteristics of pharmacokinetic parameters from routine clinical data.

Authors:  L B Sheiner; B Rosenberg; V V Marathe
Journal:  J Pharmacokinet Biopharm       Date:  1977-10

3.  Pharmacokinetic drug data.

Authors:  S Vozeh; O Schmidlin; W Taeschner
Journal:  Clin Pharmacokinet       Date:  1988-10       Impact factor: 6.447

4.  Creatinine clearance as predictor of tobramycin elimination in adult patients with cystic fibrosis.

Authors:  D J Town; A A Vinks; F Jacobs; H G Heijerman; W Bakker
Journal:  Ther Drug Monit       Date:  1996-10       Impact factor: 3.681

5.  Validation of tobramycin monitoring in adolescent and adult patients with cystic fibrosis.

Authors:  D J Touw; A A Vinks; H G Heijerman; W Bakker
Journal:  Ther Drug Monit       Date:  1993-02       Impact factor: 3.681

6.  Population pharmacokinetic models: effect of explicit versus assumed constant serum concentration assay error patterns upon parameter values of gentamicin in infants on and off extracorporeal membrane oxygenation.

Authors:  W F Dodge; R W Jelliffe; J B Zwischenberger; R A Bellanger; J A Hokanson; W R Snodgrass
Journal:  Ther Drug Monit       Date:  1994-12       Impact factor: 3.681

7.  Pharmacokinetics of tobramycin in patients with cystic fibrosis. Implications for the dosing interval.

Authors:  A M Horrevorts; J E Degener; G Dzoljic-Danilovic; M F Michel; K F Kerrebijn; O Driessen; J Hermans
Journal:  Chest       Date:  1985-08       Impact factor: 9.410

8.  Disposition of tobramycin in patients with cystic fibrosis: a prospective controlled study.

Authors:  J Levy; A L Smith; J R Koup; J Williams-Warren; B Ramsey
Journal:  J Pediatr       Date:  1984-07       Impact factor: 4.406

9.  Determining aminoglycoside dosage and blood levels using a programmable calculator.

Authors:  P K Ng
Journal:  Am J Hosp Pharm       Date:  1980-02

10.  Gentamicin population pharmacokinetic models for low birth weight infants using a new nonparametric method.

Authors:  W F Dodge; R W Jelliffe; C J Richardson; R A McCleery; J A Hokanson; W R Snodgrass
Journal:  Clin Pharmacol Ther       Date:  1991-07       Impact factor: 6.875

View more
  10 in total

Review 1.  Pharmacokinetic and Pharmacodynamic Optimization of Antibiotic Therapy in Cystic Fibrosis Patients: Current Evidences, Gaps in Knowledge and Future Directions.

Authors:  Charlotte Roy; Manon Launay; Sophie Magréault; Isabelle Sermet-Gaudelus; Vincent Jullien
Journal:  Clin Pharmacokinet       Date:  2021-01-24       Impact factor: 6.447

2.  A limited sampling strategy to estimate exposure of once-daily modified release tacrolimus in renal transplant recipients using linear regression analysis and comparison with Bayesian population pharmacokinetics in different cohorts.

Authors:  Frank Stifft; Franciscus Vandermeer; Cees Neef; Sander van Kuijk; Maarten H L Christiaans
Journal:  Eur J Clin Pharmacol       Date:  2020-02-04       Impact factor: 2.953

3.  Gentamicin pharmacokinetics in preterm infants with a patent and a closed ductus arteriosus.

Authors:  D J Touw; J H Proost; R Stevens; H N Lafeber; M M van Weissenbruch
Journal:  Pharm World Sci       Date:  2001-10

4.  Antibiotics in Adult Cystic Fibrosis Patients: A Review of Population Pharmacokinetic Analyses.

Authors:  Mehdi El Hassani; Jean-Alexandre Caissy; Amélie Marsot
Journal:  Clin Pharmacokinet       Date:  2021-01-15       Impact factor: 6.447

5.  Pharmacokinetics of tobramycin in adults with cystic fibrosis: implications for once-daily administration.

Authors:  P M Beringer; A A Vinks; R W Jelliffe; B J Shapiro
Journal:  Antimicrob Agents Chemother       Date:  2000-04       Impact factor: 5.191

6.  Population pharmacokinetics of tobramycin in patients with and without cystic fibrosis.

Authors:  Stefanie Hennig; Joseph F Standing; Christine E Staatz; Alison H Thomson
Journal:  Clin Pharmacokinet       Date:  2013-04       Impact factor: 6.447

Review 7.  Pharmacokinetic optimisation of antibacterial treatment in patients with cystic fibrosis. Current practice and suggestions for future directions.

Authors:  D J Touw; A A Vinks; J W Mouton; A M Horrevorts
Journal:  Clin Pharmacokinet       Date:  1998-12       Impact factor: 6.447

8.  Assessing Predictive Performance of Published Population Pharmacokinetic Models of Intravenous Tobramycin in Pediatric Patients.

Authors:  Celeste Bloomfield; Christine E Staatz; Sean Unwin; Stefanie Hennig
Journal:  Antimicrob Agents Chemother       Date:  2016-05-23       Impact factor: 5.191

9.  Glomerular and Tubular Renal Function after Repeated Once-Daily Tobramycin Courses in Cystic Fibrosis Patients.

Authors:  Florian Stehling; Rainer Büscher; Jörg Grosse-Onnebrink; Peter F Hoyer; Uwe Mellies
Journal:  Pulm Med       Date:  2017-01-04

10.  Population Pharmacokinetic Modeling and Dosing Simulations of Tobramycin in Pediatric Patients with Cystic Fibrosis.

Authors:  Antonin Praet; Laurent Bourguignon; Florence Vetele; Valentine Breant; Charlotte Genestet; Oana Dumitrescu; Anne Doleans-Jordheim; Philippe Reix; Sylvain Goutelle
Journal:  Antimicrob Agents Chemother       Date:  2021-07-19       Impact factor: 5.191

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.